Atara Biotherapeutics Investors Urged to Recover Losses

Robbins LLP Investigates Allegations of Misleading Investors About Drug Candidate

Apr. 16, 2026 at 10:36pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a shattered glass vial or beaker against a clean, monochromatic background, symbolizing the failure of Atara's drug candidate and the risks faced by the company.The shattered remnants of Atara's failed drug candidate tabelecleucel reflect the company's regulatory and financial troubles.San Diego Today

Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. The lawsuit alleges that Atara misled investors about the prospects of its lead drug candidate, tabelecleucel, and failed to disclose manufacturing issues and design flaws in the ALLELE study that made FDA approval unlikely.

Why it matters

Atara Biotherapeutics is a biotech company focused on developing therapies for solid tumors, blood cancers, and autoimmune diseases. The failure of its lead drug candidate, tabelecleucel, could have significant financial and reputational consequences for the company.

The details

According to the complaint, Atara failed to disclose that manufacturing issues and flaws in the ALLELE study made it unlikely the FDA would approve tabelecleucel. On January 12, 2026, Atara announced the FDA had issued another Complete Response Letter rejecting the tabelecleucel application, citing the ALLELE trial's "interpretability" issues. This news caused Atara's stock price to plummet 57%.

  • The class period is May 20, 2024 to January 9, 2026.
  • Atara resubmitted the tabelecleucel BLA to the FDA in July 2025.
  • On January 12, 2026, Atara announced the FDA had issued another Complete Response Letter rejecting the tabelecleucel application.

The players

Robbins LLP

A law firm representing a class of Atara Biotherapeutics investors who purchased securities during the class period.

Atara Biotherapeutics, Inc.

A biotech company developing therapies for solid tumors, blood cancers, and autoimmune diseases, including the lead drug candidate tabelecleucel.

Got photos? Submit your photos here. ›

What’s next

Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by May 22, 2026.

The takeaway

This case highlights the risks investors face when biotech companies fail to fully disclose issues with their drug development pipelines, underscoring the importance of thorough due diligence when investing in the volatile pharmaceutical sector.